Study on systemic immune tolerance induction in rat islet transplantation by intravenous infusion of sertoli cells

Transplantation

Volumn 89, Issue 12, 2010, Pages 1430-1437

  Li, Yang ^a   Xue, Wu Jun ^a   Tian, Xiao Hui ^a   Feng, Xin Shun ^a   Ding, Xiao Ming ^a   Song, Huan Jin ^a   Song, Yong ^a   Luo, Xiao Hui ^a   Tian, Pu Xun ^a   Ding, Chen Guang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Immune tolerance; Infusion; Islet transplantation; Sertoli cells

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; INSULIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; INSULIN SYNTHESIS; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RAT; SERTOLI CELL; STREPTOZOCIN DIABETES; SURVIVAL TIME;

ANIMALS; ANTIGENS, CD95; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; IMMUNE TOLERANCE; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; INTERLEUKIN-4; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; LIGANDS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SERTOLI CELLS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77954086218     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181da607e     Document Type: Article

References (39)

1. Shapiro AMJ, Lakey JR, Paty BW, et al. Strategic opportunities in clinical islet transplantation. Transplantation 2005; 79: 1304.
2. Hering BJ. Achieving and maintaining insulin independence in human islet transplant recipients. Transplantation 2005; 79: 1296.
3. Selawry HP, Cameron DF. Sertoli cell-enriched fractions in successful islet cell transplantation. Cell Transplant 1993; 2: 123.
4. Dufour JM, Rajotte RV, Kin T, et al. Immunoprotection of rat islet xenografts by cotransplantation with Sertoli cells and a single injection of antilymphocyte serum. Transplantation 2003; 75: 1594.
5. Skinner MK. Cell-cell interaction in the testis. Endocr Rev 1991; 12: 45.
6. Takeda Y, Gotoh M, Dono K, et al. Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts. Diabe-tologia 1998; 41: 315.
7. Allison J, Georgiou HM, Strasser A, et al. Transgenic expression of CD95 ligand on islet/3 cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94: 3943.
8. Kang SM, Schneider DB, Lin Z, et al. Fas ligand expression in islets of langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738.
9. Muruve DA, Nicolson AG, Manfro RC, et al. Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Hum Gene Ther 1997; 8: 955.
10. Moritani M, Yoshimoto K, Wong SF, et al. Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF-/31.JClin Invest 1998; 102: 499.
11. Piccirillo CA, Chang Y, Prud'homme GJ. TGF-/31 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice. J Immunol 1998; 161: 3950.
12. Suarez-Pinzon W, Korbutt GS, Power R, et al. Testicular Sertoli cells protect islet/3 cells from autoimmune destruction in NOD mice by a transforming growth factor/31-dependent mechanism. Diabetes 2000; 49: 1810.
13. Korbutt GS, Suarez-Pinzon WL, Power RF, et al. Testicular Sertoli cells exert both protective and destructive effects on syngeneic islet grafts in non-obese diabetic mice. Diabetologia 2000; 43: 474.
14. Yang H, Wright JR Jr. Co-encapsulation of Sertoli enriched testicular cell fractions further prolongs fish-to-mouse islet xenograft survival. Transplantation 1999; 67: 815.
15. Gotoh M, Maki J, Kiyoizumi T, et al. An improved method for isolation of mouse pancreatic islets. Transplantation 1985; 40: 437.
16. Shapiro AMJ, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318.
17. Teng Y, Xue WJ, Ding XM, et al. Sertoli cell cultured in vitro and its application on islet transplantation. ChinMedJ 2005; 118: 1857.
18. Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997; 46: 317.
19. Thomas SJ, Kramer GC, Herndon DN. Burns: Military options and tactical solutions. J Trauma 2003; 54: S207.
20. Chen W, Murphy B, Waaga AM, et al. Mechanisms of indirect al-lorecognition in graft rejection: Class II MHC allopeptide-specific T cell clones transfer delayed-type hypersensitivity responses in vivo. Transplantation 1996; 62: 705.
21. Jaeger C, Brendel MD, Hering BJ, et al. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes 1997; 46:1907.
22. Lau HT, Yu M, Fontana A, et al. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273: 109.
23. Lee SH, Lee JY, Park WS, et al. Transitional cell carcinoma expresses high levels of Fas ligand in vivo. BJU Int 1999; 83: 698.
24. + T cell-mediated cytotoxicity toward thyrocytes: The importance of Fas/Fas ligand interaction inducing apoptosis of thyrocytes and the inhibitory effect of thyroid-stimulating hormone. Lab Invest 2000; 80: 135.
25. Lui WY, Lee WM, Cheng CY. TGF-betas: Their role in testicular function and Sertoli cell tight junction dynamics. Int J Androl 2003; 26: 147.
26. Haagmans BL, Hoogerbrugge JW, Themmen AP, et al. Rat test-icular germ cells and Sertoli cells release different types of bioactive transforming growth factor beta in vitro. Reprod Biol Endocrinol 2003; 1: 3.
27. Selawry HP, Kotb M, Herrod HG, et al. Production of a factor, or factors, suppressing IL-2 production and T cell proliferation by Sertoli cell-enriched preparations. Transplantation 1991; 52: 846.
28. Furukawa Y, Becker G, Stinn JL, et al. Interleukin-10 (IL-10) augments allograft arterial disease: Paradoxical effects of IL-10 in vivo. Am J Pathol 1999; 155: 1929.
29. Cosenza CA, Shirwan H, Cramer DV, et al. Intragraft cytokine gene expression in human liver allografts. Liver Transpl Surg 1995; 1: 16.
30. Zuo XJ, Matsumura Y, Prehn J, et al. Cytokine gene expression in rejection and tolerant rat lung allograft models: Analysis by RT-PCR. Transpl Immunol 1995; 3: 151.
31. Zwillich T. Diabetes research. Islet transplants not yet ready for prime time. Science 2000; 289: 531.
32. Aziz T, Hasleton P, Hann AW, et al. Transforming growth factor beta in relation to cardiac allograft vasculopathy after heart transplantation. J Thorac Cardiovasc Surg 2000; 119: 700.
33. Mottram PL, Raisanen-Sokolowski A, Glysing-Jensen T, et al. Redefining peripheral tolerance in the BALB/c to CBA mouse cardiac allograft model: Vascular and cytokine analysis after transient CD4 T cell depletion. Transplantation 1998; 66: 1510.
34. Kelso A. Th1 and Th2 subsets: Paradigms lost? Immunol Today 1995; 16: 374.
35. Dekel B, Böcher WO, Marcus H, et al. Acute cellular rejectionofhuman renal tissue by adoptive transfer of allogeneic human peripheral blood mononuclear cells into chimeric rats: Sequential gene expression of cytokines, chemokines and cytolytic effector molecules, and their regulation by CTLA-4-Ig. Int Immunol 1999; 11: 1673.
36. Matyniak JE, Reiner SL. T helper phenotype and genetic susceptibility in experimental Lyme disease. J Exp Med 1995; 181: 1251.
37. 4 T cells. Cell 1997; 89: 587.
38. Battaglia M, Stabilini A, Draghici E, et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 2006; 55: 40.
39. Waldmann H, Graca L, Cobbold S, et al. Regulatory T cells and organ transplantation. Semin Immunol 2004; 16: 119.